Skip to contentV
Valion Bio, Inc.
V
VBIOValion Bio, Inc. Q3 2025 · 10-Q
Revenue$146.00K$146.00K+15.9% vs Q3 2024 Net Income-$2.60M-$2.60MN/M vs Q3 2024 EPS, diluted—
Operating Income-$2,483,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,996,000N/M Free Cash Flowderived-$2,006,000— Margins · derivedGross margin-99.3%−134.2 pt vs Q3 2024
Operating margin-1700.7%−565.0 pt vs Q3 2024
Net margin-1778.1%−642.4 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end